REFERENCES
- Diamond M, Chen R, Xie X, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Square. 2021 Feb 10. rs.3.rs-228079. doi:https://doi.org/10.21203/rs.3.rs-228079/v1.
- Ferrareze PG, Franceschi VB, de Menezes Mayer A, et al. E484k as an innovative phylogenetic event for viral evolution: genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. bioRxiv: Preprint Server Biol. 2021:2021.01.27.426895. doi:https://doi.org/10.1101/2021.01.27.426895.
- Kupferschmidt K. Fast-spreading U.K. virus variant raises alarms. Science. 2021 Jan 1;371(6524):9–10.
- Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 Apr;27(4):622–625.
- Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 May;593(7857):130–135.
- Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv: Preprint Server Biol. 2020 Dec 28. doi:https://doi.org/10.1101/2020.12.28.424451.
- Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020 Oct 28;9:e61312. doi:https://doi.org/10.7554/eLife.61312.
- Wise J. Covid-19: the E484K mutation and the risks it poses. BMJ (Clin Res ed.). 2021 Feb 5;372:n359.
- Annavajhala MK, Mohri H, Zucker JE, et al. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. medRxiv: Preprint Server Health Sci. 2021:2021.02.23.21252259. doi:https://doi.org/10.1101/2021.02.23.21252259.
- Lasek-Nesselquist E, Lapierre P, Schneider E, et al. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York state. medRxiv: Preprint Server Health Sci. 2021:2021.02.26.21251868. doi:https://doi.org/10.1101/2021.02.26.21251868.
- Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage - United States, December 29, 2020-January 12, 2021. MMWR. 2021;70(3):95–99.
- Iacobucci G. Covid-19: new UK variant may be linked to increased death rate, early data indicate. BMJ (Clin Res ed.). 2021 Jan 26BMJ2021;372:n230. doi:https://doi.org/10.1136/bmj.n230.
- Washington NL, Gangavarapu K, Zeller M, et al. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv: Preprint Server Health Sci. 2021 Feb 7. doi:https://doi.org/10.1101/2021.02.06.21251159.
- Zhao Y, Cunningham MH, Mediavilla JR, et al. Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. Sci Rep. 2021;11(1):1–8.
- Vogels CBF, Watkins AE, Harden CA, et al. Salivadirect: a simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med. 2021;2(3):263–280.